CD14 and CD55 |
CD14 molecule |
CD55 molecule (Cromer blood group) |
- ER-Phagosome pathway
- Caspase activation via Death Receptors in the presence of ligand
- Toll Like Receptor 4 (TLR4) Cascade
- Transfer of LPS from LBP carrier to CD14
- MyD88:MAL(TIRAP) cascade initiated on plasma membrane
- MyD88-independent TLR4 cascade
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- TRIF-mediated programmed cell death
- MyD88 deficiency (TLR2/4)
- IRAK4 deficiency (TLR2/4)
- Regulation of TLR by endogenous ligand
- Neutrophil degranulation
- Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
- IKK complex recruitment mediated by RIP1
- TRAF6-mediated induction of TAK1 complex within TLR4 complex
- IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
|
- Class B/2 (Secretin family receptors)
- Neutrophil degranulation
- COPI-mediated anterograde transport
- Regulation of Complement cascade
|
|
|
|
- Complement regulatory protein defects, including the following six diseases: C1 inhibitor deficiency (hereditary angioedema); C4 binding protein alpha deficiency; C4 binding protein beta deficiency; Factor I deficiency; Decay-accelerating factor (CD55) deficiency; CD59 deficiency
|
MS4A1 and LMNA |
membrane spanning 4-domains A1 |
lamin A/C |
|
- XBP1(S) activates chaperone genes
- Signaling by BRAF and RAF fusions
|
- Rituximab
- Ibritumomab tiuxetan
- Tositumomab
- Ofatumumab
- Obinutuzumab
- Ocrelizumab
|
|
|
- Restrictive dermopathy
- Emery-Dreifuss muscular dystrophy
- Dilated cardiomyopathy (DCM)
- Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
- Mandibuloacral dysplasia
- Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
- Limb-girdle muscular dystrophy (LGMD)
- Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
- Hutchinson-Gilford progeria syndrome
|
CD28 and PIK3CG |
CD28 molecule |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma |
- PIP3 activates AKT signaling
- Nef mediated downregulation of CD28 cell surface expression
- Constitutive Signaling by Aberrant PI3K in Cancer
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- CD28 dependent Vav1 pathway
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
- GPVI-mediated activation cascade
- Synthesis of PIPs at the plasma membrane
- G beta:gamma signalling through PI3Kgamma
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
|
|
- Staurosporine
- Myricetin
- LY-294002
- Quercetin
- 5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE
- XL765
- 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE
- N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE
- 5,5-dimethyl-2-morpholin-4-yl-5,6-dihydro-1,3-benzothiazol-7(4H)-one
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- (5E)-5-[(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)METHYLENE]-1,3-THIAZOLIDINE-2,4-DIONE
- (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
- 1-methyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
|
|
|
SCARB2 and LMNA |
scavenger receptor class B member 2 |
lamin A/C |
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
|
- XBP1(S) activates chaperone genes
- Signaling by BRAF and RAF fusions
|
|
|
- Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)
|
- Restrictive dermopathy
- Emery-Dreifuss muscular dystrophy
- Dilated cardiomyopathy (DCM)
- Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
- Mandibuloacral dysplasia
- Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
- Limb-girdle muscular dystrophy (LGMD)
- Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
- Hutchinson-Gilford progeria syndrome
|
ENTPD3 and LMNA |
ectonucleoside triphosphate diphosphohydrolase 3 |
lamin A/C |
- Phosphate bond hydrolysis by NTPDase proteins
|
- XBP1(S) activates chaperone genes
- Signaling by BRAF and RAF fusions
|
|
|
|
- Restrictive dermopathy
- Emery-Dreifuss muscular dystrophy
- Dilated cardiomyopathy (DCM)
- Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
- Mandibuloacral dysplasia
- Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
- Limb-girdle muscular dystrophy (LGMD)
- Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
- Hutchinson-Gilford progeria syndrome
|
CD72 and LMNA |
CD72 molecule |
lamin A/C |
- Other semaphorin interactions
|
- XBP1(S) activates chaperone genes
- Signaling by BRAF and RAF fusions
|
|
|
|
- Restrictive dermopathy
- Emery-Dreifuss muscular dystrophy
- Dilated cardiomyopathy (DCM)
- Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
- Mandibuloacral dysplasia
- Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
- Limb-girdle muscular dystrophy (LGMD)
- Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
- Hutchinson-Gilford progeria syndrome
|
CD74 and HLA-DPB1 |
CD74 molecule |
major histocompatibility complex, class II, DP beta 1 |
- Cell surface interactions at the vascular wall
- MHC class II antigen presentation
|
- Downstream TCR signaling
- Phosphorylation of CD3 and TCR zeta chains
- Translocation of ZAP-70 to Immunological synapse
- Generation of second messenger molecules
- MHC class II antigen presentation
- PD-1 signaling
- Interferon gamma signaling
|
|
|
|
- Dilated cardiomyopathy (DCM)
|
CD74 and HADHA |
CD74 molecule |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
- Cell surface interactions at the vascular wall
- MHC class II antigen presentation
|
- Acyl chain remodeling of CL
- Beta oxidation of myristoyl-CoA to lauroyl-CoA
- mitochondrial fatty acid beta-oxidation of unsaturated fatty acids
- Beta oxidation of palmitoyl-CoA to myristoyl-CoA
- Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA
- Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA
- Beta oxidation of octanoyl-CoA to hexanoyl-CoA
- Beta oxidation of hexanoyl-CoA to butanoyl-CoA
|
|
|
|
- Disorders of fatty-acid oxidation, including: Medium-chain (MC) acyl-CoA dehydrogenase (AD) deficiency (MCADD); Short-chain AD deficiency (SCADD) ; Short-branched-chain AD deficiency (SBCADD) ; Very long-chain AD deficiency (VLCADD) ; Long-chain 3-hydroxyacyl CoA dehydrogenase deficiency (LCHADD) ; Trifunctional protein deficiency (TFP); Carnitine palmitoyltransferase deficiency (CPT); Carnitine-acylcarnitine translocase deficiency (CACT); Systemic primary carnitine deficiency (CDSP)
- Mitochondrial respiratory chain deficiencies (MRCD), including: Mitochondrial complex I deficiency (MT-C1D); Complex II deficiency (MT-C2D); Complex III deficiency (MT-C3D); Complex IV deficiency (MT-C4D); Complex V deficiency (MT-ATPSD); Leigh syndrome (LS); Kearns-Sayre Syndrome (KSS); LCHD deficiency (LCHD); Leber Hereditary Optic Neuropathy (LHON); Myoclonic Epilepsy and Ragged-Red Fiber Disease (MERRF); NARP; MELAS; ACAD9 deficiency; HADH deficiency; HIBCH deficiency; GRACILE syndrome
|
CD79A and JCHAIN |
CD79a molecule |
joining chain of multimeric IgA and IgM |
- CD22 mediated BCR regulation
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
- Cell surface interactions at the vascular wall
- Scavenging of heme from plasma
|
|
|
- Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
|
|
CD81 and LMNA |
CD81 molecule |
lamin A/C |
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Regulation of Complement cascade
|
- XBP1(S) activates chaperone genes
- Signaling by BRAF and RAF fusions
|
|
|
|
- Restrictive dermopathy
- Emery-Dreifuss muscular dystrophy
- Dilated cardiomyopathy (DCM)
- Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
- Mandibuloacral dysplasia
- Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
- Limb-girdle muscular dystrophy (LGMD)
- Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
- Hutchinson-Gilford progeria syndrome
|
ADGRE5 and CD55 |
adhesion G protein-coupled receptor E5 |
CD55 molecule (Cromer blood group) |
- Class B/2 (Secretin family receptors)
- Neutrophil degranulation
|
- Class B/2 (Secretin family receptors)
- Neutrophil degranulation
- COPI-mediated anterograde transport
- Regulation of Complement cascade
|
|
|
|
- Complement regulatory protein defects, including the following six diseases: C1 inhibitor deficiency (hereditary angioedema); C4 binding protein alpha deficiency; C4 binding protein beta deficiency; Factor I deficiency; Decay-accelerating factor (CD55) deficiency; CD59 deficiency
|
CDK1 and LMNA |
cyclin dependent kinase 1 |
lamin A/C |
- MAPK3 (ERK1) activation
- E2F-enabled inhibition of pre-replication complex formation
- Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
- Golgi Cisternae Pericentriolar Stack Reorganization
- Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes
- APC/C:Cdc20 mediated degradation of Cyclin B
- Cdc20:Phospho-APC/C mediated degradation of Cyclin A
- Regulation of APC/C activators between G1/S and early anaphase
- Phosphorylation of the APC/C
- Phosphorylation of Emi1
- Condensation of Prophase Chromosomes
- MASTL Facilitates Mitotic Progression
- Resolution of Sister Chromatid Cohesion
- Condensation of Prometaphase Chromosomes
- Regulation of PLK1 Activity at G2/M Transition
- Activation of NIMA Kinases NEK9, NEK6, NEK7
- Initiation of Nuclear Envelope (NE) Reformation
- Nuclear Pore Complex (NPC) Disassembly
- Loss of Nlp from mitotic centrosomes
- Recruitment of mitotic centrosome proteins and complexes
- Loss of proteins required for interphase microtubule organization from the centrosome
- Recruitment of NuMA to mitotic centrosomes
- Depolymerisation of the Nuclear Lamina
- Anchoring of the basal body to the plasma membrane
- MAPK6/MAPK4 signaling
- Ovarian tumor domain proteases
- TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
- Regulation of TP53 Degradation
- Mitotic Prophase
- G1/S-Specific Transcription
- Cyclin A/B1/B2 associated events during G2/M transition
- Cyclin A/B1/B2 associated events during G2/M transition
- G2/M DNA replication checkpoint
- Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
- The role of GTSE1 in G2/M progression after G2 checkpoint
- AURKA Activation by TPX2
- Transcriptional regulation by RUNX2
|
- XBP1(S) activates chaperone genes
- Signaling by BRAF and RAF fusions
|
- Indirubin-3'-Monoxime
- Olomoucine
- Hymenialdisine
- SU9516
- Alvocidib
- Alsterpaullone
- AT7519
|
|
|
- Restrictive dermopathy
- Emery-Dreifuss muscular dystrophy
- Dilated cardiomyopathy (DCM)
- Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
- Mandibuloacral dysplasia
- Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
- Limb-girdle muscular dystrophy (LGMD)
- Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
- Hutchinson-Gilford progeria syndrome
|
CDK1 and PLEC |
cyclin dependent kinase 1 |
plectin |
- MAPK3 (ERK1) activation
- E2F-enabled inhibition of pre-replication complex formation
- Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
- Golgi Cisternae Pericentriolar Stack Reorganization
- Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes
- APC/C:Cdc20 mediated degradation of Cyclin B
- Cdc20:Phospho-APC/C mediated degradation of Cyclin A
- Regulation of APC/C activators between G1/S and early anaphase
- Phosphorylation of the APC/C
- Phosphorylation of Emi1
- Condensation of Prophase Chromosomes
- MASTL Facilitates Mitotic Progression
- Resolution of Sister Chromatid Cohesion
- Condensation of Prometaphase Chromosomes
- Regulation of PLK1 Activity at G2/M Transition
- Activation of NIMA Kinases NEK9, NEK6, NEK7
- Initiation of Nuclear Envelope (NE) Reformation
- Nuclear Pore Complex (NPC) Disassembly
- Loss of Nlp from mitotic centrosomes
- Recruitment of mitotic centrosome proteins and complexes
- Loss of proteins required for interphase microtubule organization from the centrosome
- Recruitment of NuMA to mitotic centrosomes
- Depolymerisation of the Nuclear Lamina
- Anchoring of the basal body to the plasma membrane
- MAPK6/MAPK4 signaling
- Ovarian tumor domain proteases
- TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
- Regulation of TP53 Degradation
- Mitotic Prophase
- G1/S-Specific Transcription
- Cyclin A/B1/B2 associated events during G2/M transition
- Cyclin A/B1/B2 associated events during G2/M transition
- G2/M DNA replication checkpoint
- Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
- The role of GTSE1 in G2/M progression after G2 checkpoint
- AURKA Activation by TPX2
- Transcriptional regulation by RUNX2
|
- Assembly of collagen fibrils and other multimeric structures
- Caspase-mediated cleavage of cytoskeletal proteins
- Type I hemidesmosome assembly
|
- Indirubin-3'-Monoxime
- Olomoucine
- Hymenialdisine
- SU9516
- Alvocidib
- Alsterpaullone
- AT7519
|
|
|
- Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
- Epidermolysis bullosa, hemidesmosomal, including: Epidermolysis bullosa, generalized atrophic benign (GABEB); Epidermolysis bullosa simplex with pyloric atresia (EBS-PA); Epidermolysis bullosa simplex with muscular dystrophy (EBS-MD); Epidermolysis bullosa simplex, Ogna type (EBS-Ogna)
|
CDK11B and YWHAZ |
cyclin dependent kinase 11B |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta |
- Recruitment of mitotic centrosome proteins and complexes
|
- Activation of BAD and translocation to mitochondria
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Deactivation of the beta-catenin transactivating complex
- Rap1 signalling
- GP1b-IX-V activation signalling
- KSRP (KHSRP) binds and destabilizes mRNA
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RHO GTPases activate PKNs
- TP53 Regulates Metabolic Genes
- Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
- NOTCH4 Activation and Transmission of Signal to the Nucleus
- Negative regulation of NOTCH4 signaling
- Regulation of localization of FOXO transcription factors
|
|
|
|
|
CDC5L and YWHAZ |
cell division cycle 5 like |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta |
- mRNA Splicing - Major Pathway
|
- Activation of BAD and translocation to mitochondria
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Deactivation of the beta-catenin transactivating complex
- Rap1 signalling
- GP1b-IX-V activation signalling
- KSRP (KHSRP) binds and destabilizes mRNA
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RHO GTPases activate PKNs
- TP53 Regulates Metabolic Genes
- Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
- NOTCH4 Activation and Transmission of Signal to the Nucleus
- Negative regulation of NOTCH4 signaling
- Regulation of localization of FOXO transcription factors
|
|
|
|
|
CDC25A and CAMK1D |
cell division cycle 25A |
calcium/calmodulin dependent protein kinase ID |
- Transcription of E2F targets under negative control by DREAM complex
- Polo-like kinase mediated events
- Activation of ATR in response to replication stress
- Ub-specific processing proteases
- Cyclin E associated events during G1/S transition
- Cyclin A/B1/B2 associated events during G2/M transition
- Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
- Cyclin A:Cdk2-associated events at S phase entry
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
|
|
|
- N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE
|
|
|
CDC25A and YWHAZ |
cell division cycle 25A |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta |
- Transcription of E2F targets under negative control by DREAM complex
- Polo-like kinase mediated events
- Activation of ATR in response to replication stress
- Ub-specific processing proteases
- Cyclin E associated events during G1/S transition
- Cyclin A/B1/B2 associated events during G2/M transition
- Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
- Cyclin A:Cdk2-associated events at S phase entry
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
|
- Activation of BAD and translocation to mitochondria
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Deactivation of the beta-catenin transactivating complex
- Rap1 signalling
- GP1b-IX-V activation signalling
- KSRP (KHSRP) binds and destabilizes mRNA
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RHO GTPases activate PKNs
- TP53 Regulates Metabolic Genes
- Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
- NOTCH4 Activation and Transmission of Signal to the Nucleus
- Negative regulation of NOTCH4 signaling
- Regulation of localization of FOXO transcription factors
|
|
|
|
|
CDC25B and YWHAZ |
cell division cycle 25B |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta |
- Cyclin A/B1/B2 associated events during G2/M transition
- Cyclin A:Cdk2-associated events at S phase entry
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
|
- Activation of BAD and translocation to mitochondria
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Deactivation of the beta-catenin transactivating complex
- Rap1 signalling
- GP1b-IX-V activation signalling
- KSRP (KHSRP) binds and destabilizes mRNA
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RHO GTPases activate PKNs
- TP53 Regulates Metabolic Genes
- Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
- NOTCH4 Activation and Transmission of Signal to the Nucleus
- Negative regulation of NOTCH4 signaling
- Regulation of localization of FOXO transcription factors
|
|
|
|
|
CDC25C and YWHAZ |
cell division cycle 25C |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta |
- Polo-like kinase mediated events
- Activation of ATR in response to replication stress
- RHO GTPases activate PKNs
- TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
- TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
- Cyclin A/B1/B2 associated events during G2/M transition
- Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
|
- Activation of BAD and translocation to mitochondria
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Deactivation of the beta-catenin transactivating complex
- Rap1 signalling
- GP1b-IX-V activation signalling
- KSRP (KHSRP) binds and destabilizes mRNA
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RHO GTPases activate PKNs
- TP53 Regulates Metabolic Genes
- Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
- NOTCH4 Activation and Transmission of Signal to the Nucleus
- Negative regulation of NOTCH4 signaling
- Regulation of localization of FOXO transcription factors
|
|
|
|
|
CDC42 and NCF2 |
cell division cycle 42 |
neutrophil cytosolic factor 2 |
- GPVI-mediated activation cascade
- EGFR downregulation
- Rho GTPase cycle
- Regulation of actin dynamics for phagocytic cup formation
- Regulation of actin dynamics for phagocytic cup formation
- CD28 dependent Vav1 pathway
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- DCC mediated attractive signaling
- Inactivation of CDC42 and RAC1
- VEGFA-VEGFR2 Pathway
- Myogenesis
- Myogenesis
- RHO GTPases activate KTN1
- RHO GTPases activate IQGAPs
- RHO GTPases activate PAKs
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate Formins
- RHO GTPases Activate Formins
- MAPK6/MAPK4 signaling
- Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
- G beta:gamma signalling through CDC42
- FCGR3A-mediated phagocytosis
- FCGR3A-mediated phagocytosis
- Factors involved in megakaryocyte development and platelet production
|
- ROS and RNS production in phagocytes
- Cross-presentation of particulate exogenous antigens (phagosomes)
- Detoxification of Reactive Oxygen Species
- VEGFA-VEGFR2 Pathway
- RHO GTPases Activate NADPH Oxidases
|
- Aminophosphonic Acid-Guanylate Ester
- Guanosine-5'-Diphosphate
|
|
|
- Chronic granulomatous disease, including the following four diseases: X-linked CGD (gp91 phox CGD); p22phox deficiency (p22phox CGD); p47phox deficiency (p47phox CGD); p67phox deficiency (p67phox CGD)
|